Jennerex to present key data on JX-594 Phase 1 dose escalation clinical study at ASGCT Annual Meeting

May 14 2010

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced that key data from its JX-594 intravenous administration Phase 1 dose escalation clinical study will be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 19-22, 2010, in Washington DC.

The presentation details are as follows:

• Abstract #33: "Demonstration of Delivery and Antitumoral Activity of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, Following a Single Intravenous Infusion in Patients with Refractory Metastatic Cancers"
• Oral presentation to be made on May 20, 2010, 2:00 p.m. EDT by David H. Kirn, M.D., president and chief executive officer of Jennerex, in the "Cancer-Oncolytic Viruses I" session.